Pharos Capital Launches Verdi Oncology through Horizon Oncology Acquisition

We represented Pharos Capital Group in its acquisition of Horizon Oncology. The acquisition marks the launch of Verdi Oncology, Inc., an oncology practice and clinical research management company. Financial terms of the transaction were not publicly disclosed.

Horizon Oncology offers a wide range of comprehensive cancer services to patients, including advanced technological options, premier clinical expertise and cutting edge clinical trials opportunities, with a focus on early phase trials.

Pharos Capital Group is an SEC Registered Investment Advisor. As of March 2018, Pharos has invested in 51 companies and currently has over $690 million of private equity assets under management.

You Also May Be Interested In:

  • Served as fund formation counsel for the formation, capitalization, closing and operation of Brown Robin Partners’ current fund.

    We served as fund formation counsel for the formation, capitalization, closing and operation of Brown Robin Partners’ current fund.
  • Representing Tivity Health Inc. (Nasdaq: TVTY), a leading provider of healthy life-changing solutions, in their agreement to be acquired by funds managed by Stone Point Capital, with over $40 billion of assets under management; under the terms of the agreement, Tivity Health stockholders will receive $32.50 in cash per share, representing a total transaction value of $2.0 billion

    We are representing Tivity Health Inc. (Nasdaq: TVTY), a leading provider of healthy life-changing solutions, in their agreement to be...
    Client Type: Public Company
  • Representation of Groups360, a leading platform for booking group travel, in its $35,000,000 investment from  Zigg Capital, Blackstone Innovations Investments, and Fir Tree Partners to accelerate growth.

    We represented Groups360, a leading platform for booking group travel, in its $35,000,000 investment from Zigg Capital, Blackstone Innovations Investments,...